The majority of contracts on pharmaceuticals, medical devices and other Life Science related products in Europe are concluded with public entities. Advice on Procurement Law brings foreign companies an advantage in successfully winning relevant market shares. The related chances and benefits are often unknown to newcomers on the European market.
Germany: 60 % of market for generic drugs subject to procurement proceedings
An example of the relevance of procurement law for a successful market entry is the situation on the German market for generic drugs. About 90 % of the German population (an impressive number of 70.12 Mio. people) receive health care from statutory health insurance companies (see: https://www.gkv-spitzenverband.de/english/statutory_health_insurance/statutory_health_insurance.jsp (English, last retrieved on 12/02/2016)). These public sickness funds are the main actors in the German social security system and are financed by a state-regulated system of social insurance contributions to be paid by the insured persons. For reasons of cost-effectiveness, German public health insurance companies are obligated by law to conclude a certain type of rebate contract with pharmaceutical companies, building up a complex contractual system which basically ensures an exclusive right for the pharmaceutical company in exchange for a rebate on the generic drug. This legal framework leads to a market situation in which 60% of the market for generics is covered by public contracts with German public health insurance companies (source: http://www.progenerika.de/wp-content/uploads/2015/06/Marktdaten-April-2015.pdf (German, last retrieved on 12/02/2016)).
Requirement of public tender proceedings
Resulting from a judgment by the European Court of Justice (CJEU, C-300/07 - Hans & Christophorus Oymanns), all public health insurance companies in Germany are obligated to tender contracts they conclude with private companies. This includes not only the aforementioned rebate contracts but all contracts for goods and services required by the insured persons. For instance, the range of such contracts may include goods and services relating to wheelchairs, sleep therapy device,s biosimilars, blood glucose monitoring systems, and even medical apps. Given the market share of public health insurance companies, the obligation to tender can be a crucial benefit for non-European companies. Though organized in different ways, basically all European member states have publicly organized healthcare systems. As a result, the aforementioned obligation to tender is a factor relevant to other contracting authorities, not only in Germany – resulting in the chance for Non-European companies to win relevant market shares in Europe.
Transparent and non-discriminatory access for foreign companies
Regulated by European Procurement law and its national transposition, contracting public entities have to comply with a number of formal requirements and general principles. These formalities and principles become relevant at different stages of the procurement proceeding:
Legal Remedies
As indicated, there are quite a number of legal remedies to ensure compliance with Procurement Law and to prevent unfair treatment of bidders. Especially for non-European companies, these remedies should guarantee non-discriminatory access to relevant markets in the life science sector. They can also be used to challenge a public authorities’ decision to award a competitor. However, it is important to note that a successful challenge of a tender or an award decision depends on reacting immediately to every potential violation of Procurement Law.
The provisions of Procurement Law may vary in their implementation in the different member states of the European Union – however, public tenders give an opportunity for market entry that should not be ignored.
This article is part of the International Life Sciences Update for April 2016